This week at the Wonderland Psychedelic Convention in Miami, Chairman of the Bitcoin Foundation, Economist, and Philanthropist Brock Pierce announced that he is partnering with Jeremy Gardner, the Managing Partner and Founder of Mystic Ventures, as a General Partner in this cutting-edge venture fund. Pierce is the co-founder of EOS Alliance, Block.one, Blockchain Capital, Tether, and Mastercoin, the sector’s first ICO. Gardner is the Founder of Blockchain Education Network, Co-founder of Augur, the world’s first Utility Token and first ICO on Ethereum.
Pierce has been a long supporter of MAPS, the Multidisciplinary Association for Psychedelic Studies. He is also a pre-IPO investor in ATAI Life Sciences, a Germany-based clinical-stage biopharmaceutical company. As an investor in Filament Health, a Canadian-based clinical-stage natural psychedelic development company, Pierce is a veteran in this important new sector.
Also Read: Alphawave IP Receives 2022 TSMC OIP Partner of the Year Award for High-Speed SerDes IP Innovations
Mystic is an AngelList Ventures Fund focused on the medicinal applications of psychedelics. Mystic Ventures functions like a biotech venture fund, oriented towards scientific breakthroughs and new applications of promising therapeutics and plant medicines. Mystic is dedicated to driving these advanced research and development teams, often from pharmaceutical companies and top research universities, to develop cost-effective solutions that are less exploitive, addictive, and focused on holistic healing rather than ongoing treatment. Mystic and their portfolio are working to make psychedelic medicines and therapies mainstream.
Mystic Ventures is a rolling fund on AngelList Ventures. It’s a standard 2:20 (management/carry) with a $25,000 minimum quarterly ticket size for a commitment of 8 quarters. The fund’s Investments range from AI-powered drug discovery to the development of new treatments, as well as far-ranging startups such as a breathwork app and biofeedback powered haptic sound startup.